235 related articles for article (PubMed ID: 25212456)
1. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
Br J Haematol; 2015 Jan; 168(2):284-90. PubMed ID: 25212456
[TBL] [Abstract][Full Text] [Related]
2. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
[TBL] [Abstract][Full Text] [Related]
3. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhang Y; Cappellini MD
Am J Hematol; 2013 Jun; 88(6):503-6. PubMed ID: 23553596
[TBL] [Abstract][Full Text] [Related]
5. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
Shirley M; Plosker GL
Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX
Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622
[TBL] [Abstract][Full Text] [Related]
8. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
11. The impact of liver steatosis on the ability of serum ferritin levels to be predictive of liver iron concentration in non-transfusion-dependent thalassaemia patients.
Ricchi P; Meloni A; Spasiano A; Costantini S; Pepe A; Cinque P; Filosa A
Br J Haematol; 2018 Mar; 180(5):721-726. PubMed ID: 29363758
[TBL] [Abstract][Full Text] [Related]
12. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
[TBL] [Abstract][Full Text] [Related]
13. Correlation between liver iron concentration determined by magnetic resonance imaging and serum ferritin in adolescents with thalassaemia disease.
Chuansumrit A; Laothamathat J; Sirachainan N; Sungkarat W; Wongwerawattanakoon P; Kumkrua P
Paediatr Int Child Health; 2016 Aug; 36(3):203-8. PubMed ID: 27595699
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
[TBL] [Abstract][Full Text] [Related]
15. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.
Viprakasit V; Ibrahim H; Ha SY; Ho PJ; Li CK; Chan LL; Chiu CF; Sutcharitchan P; Habr D; Domokos G; Roubert B; Xue HL; Bowden DK; Lin KH
Int J Hematol; 2011 Mar; 93(3):319-328. PubMed ID: 21374076
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhu Z; Cappellini MD
Ann Hematol; 2013 Nov; 92(11):1485-93. PubMed ID: 23775581
[TBL] [Abstract][Full Text] [Related]
18. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
Eur J Haematol; 2014 Jun; 92(6):521-6. PubMed ID: 24460655
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassaemias - response to Ang et al.
Taher AT
Br J Haematol; 2017 Mar; 176(6):989-990. PubMed ID: 26969908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
